``Medical Device Daily'' Spotlights Cardima-Sponsored Atrial Fibrillation Symposium; Full-Text article available at www.cardima.com.Business Editors & Health/Medical Writers FREMONT, Calif.--(BW HealthWire)--Nov. 30, 2001 Cardima(R), Inc. (Nasdaq: CRDM CRDM Control Rod Drive Mechanism CRDM Centre for Rapid Design and Manufacture (Buckinghamshire Chilterns University) CRDM Cumann Rince Dea Mheasa (Irish dancing organisation) ) -- developer of the REVELATION(TM) Tx and the REVELATION Helix(TM) microcatheter systems -- today announced that a Company-sponsored symposium on the treatment of atrial fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. (AF) was featured as the lead article in the Nov. 19, 2001 issue of "Medical Device Daily." The symposium, titled, "New Devices and Approaches for Atrial Fibrillation (AF); Advances in Radiofrequency (RF) Linear Ablation," was held Nov. 13, 2001 at the American Heart Association's (AHA) annual Scientific Sessions. The full text of the "Medical Device Daily" article is available on the Company's Web site at www.cardima.com. The article includes comments by the symposium's moderator, Warren M. Jackman, M.D., professor of Medicine and director of Clinical Electrophysiology, University of Oklahoma University of Oklahoma, abbreviated OU, is a coeducational public research university located in the U.S. state of Oklahoma. Founded in 1890, it existed in Oklahoma Territory near Indian Territory 17 years before the two became the state of Oklahoma. , as well as by panelists Angelo A. V. de Paola, M.D., director of Cardiology, Federal University of Sao Paulo, Brazil; Hugh Calkins Hugh Calkins (born 1924) was a member of the Harvard Corporation from 1969 to 1984. He was born in Newton, Ohio in 1924, and he went to Exeter before coming to Harvard. As an undergraduate, he served briefly as president of the Harvard Crimson in 1942. , M.D., professor of Medicine and director of Electrophysiology Services, Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. ; Thorston Lewalter, M.D., University of Bonn The University of Bonn (German: Rheinische Friedrich-Wilhelms-Universität Bonn) is a public research university located in Bonn, Germany. Founded in 1818 the University of Bonn is nowadays one of the largest universities in Germany. , Germany; and Abraham Kocheril, M.D., head of Cardiac Electrophysiology, Carle Clinic, University of Illinois University of Illinois may refer to:
The article discusses ongoing studies using Cardima's products, including early clinical results and observations from the European study of the REVELATION Helix for the circumferential mapping and ablation of the pulmonary vein pulmonary vein n. A vein that carries oxygenated blood from the lungs to the left atrium of the heart. , and current preliminary results from the U.S. right-sided linear ablation trial of the REVELATION Tx system. The article further notes that results from a 29-patient independent investigator independent investigator Independent research investigator NIHspeak A well-established scientist whose research accomplishments have resulted in the bestowal of "tenure", ie, long-term commitment of salary, personnel and research resources study of the REVELATION Tx system will be issued in December 2001. "Our AHA symposium featured a lively discussion by various industry luminaries, and we were delighted with the number and caliber of professionals attending the standing-room-only event," said Gabriel Vegh, chief executive officer of Cardima. Cardima, Inc. developed its patented, unique series of REVELATION microcatheter systems for the mapping and treatment of AF, which the Company believes is a potential $6 billion market that is poorly served by current treatment alternatives. AF afflicts an estimated 4.5 million people worldwide. The REVELATION series of microcatheters is a minimally invasive, single-use microcatheter for potentially curing AF. Cardima has enrollment in a Phase III study underway in the U.S. for its Revelation Tx linear ablation microcatheter system. The Company is targeting U.S. approval before the end of 2002. Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 filed with the Securities and Exchange Commission on March 22, 2001, and subsequent Form 10-Qs issued in 2001. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion